Published in Ann Rheum Dis on November 27, 2007
Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol (2015) 0.94
Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis. Arthritis Res Ther (2009) 0.89
Attenuation of CCl4-induced hepatic fibrosis in mice by vaccinating against TGF-β1. PLoS One (2013) 0.87
Therapeutic vaccination with TNF-Kinoid in TNF antagonist-resistant rheumatoid arthritis: a phase II randomized, controlled clinical trial. PLoS One (2014) 0.85
Protection from articular damage by passive or active anti-tumour necrosis factor (TNF)-α immunotherapy in human TNF-α transgenic mice depends on anti-TNF-α antibody levels. Clin Exp Immunol (2013) 0.84
Modulation of anti-tumor necrosis factor alpha (TNF-α) antibody secretion in mice immunized with TNF-α kinoid. Clin Vaccine Immunol (2012) 0.79
IL-1 Vaccination Is Suitable for Treating Inflammatory Diseases. Front Pharmacol (2017) 0.75
Long-term cultures of HTLV-III--infected T cells: a model of cytopathology of T-cell depletion in AIDS. Science (1986) 5.86
HTLV-III in cells cultured from semen of two patients with AIDS. Science (1984) 3.47
Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis. Arthritis Rheumatol (2014) 2.84
New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J Immunol (1999) 2.76
High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol (1997) 2.59
Tetanus toxin. Microbiol Rev (1979) 2.25
Imaging of atypical hemangiomas of the liver with pathologic correlation. Radiographics (2000) 2.15
Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. Aliment Pharmacol Ther (2014) 2.11
Is trauma in Switzerland any different? epidemiology and patterns of injury in major trauma - a 5-year review from a Swiss trauma centre. Swiss Med Wkly (2014) 2.07
Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther (2004) 2.04
Adjuvants--a balance between toxicity and adjuvanticity. Vaccine (1993) 1.86
Immunoglobulin synthesis and secretion. II. Radioautographic studies of sites of addition of carbohydrate moieties and intracellular transport. J Cell Biol (1970) 1.78
Functional consequences of a polymorphism affecting NF-kappaB p50-p50 binding to the TNF promoter region. Mol Cell Biol (2000) 1.74
Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci U S A (1998) 1.68
Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol (1999) 1.65
Biphasic effect of interferon-gamma in murine collagen-induced arthritis. Eur J Immunol (1995) 1.63
Radiofrequency liver ablation: experimental comparative study of water-cooled versus expandable systems. AJR Am J Roentgenol (2001) 1.61
Hepatitis B virus DNA sequences in lymphoid cells from patients with AIDS and AIDS-related complex. Science (1985) 1.60
C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci U S A (1998) 1.57
Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol (2000) 1.57
Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Nature (1988) 1.53
Percutaneous drainage versus emergency cholecystectomy for the treatment of acute cholecystitis in critically ill patients: does it matter? World J Surg (2011) 1.52
Focal sparing of liver parenchyma in steatosis: role of the gallbladder and its vessels. J Ultrasound Med (1995) 1.49
Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule. Infect Immun (1984) 1.45
Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci U S A (2000) 1.42
Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. J Hum Virol (1999) 1.38
Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut (1998) 1.37
Renal cell carcinoma containing fat: demonstration with CT. Radiology (1993) 1.29
An antigenic polypeptide fragment isolated from tetanus toxin: chemical characterization, binding to gangliosides and retrograde axonal transport in various neuron systems. J Neurochem (1977) 1.26
Lovastatin inhibits HIV-1 expression in H9 human T lymphocytes cultured in cholesterol-poor medium. Biomed Pharmacother (1994) 1.23
Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study). J Acquir Immune Defic Syndr Hum Retrovirol (1999) 1.20
Detection of infectious HTLV-III/LAV virus in cell-free plasma from AIDS patients. Lancet (1985) 1.19
Cytopathic effect of human immunodeficiency virus in T4 cells is linked to the last stage of virus infection. Proc Natl Acad Sci U S A (1988) 1.19
Even transcriptionally competent proviruses are silent in bovine leukemia virus-induced sheep tumor cells. Proc Natl Acad Sci U S A (1988) 1.19
Patterns of genomic sequence diversity among their simian immunodeficiency viruses suggest that L'Hoest monkeys (Cercopithecus lhoesti) are a natural lentivirus reservoir. J Virol (2000) 1.17
Binding of HIV-1 to RBCs involves the Duffy antigen receptors for chemokines (DARC). Biomed Pharmacother (1998) 1.16
Amygdala atrophy in Alzheimer's disease. An in vivo magnetic resonance imaging study. Arch Neurol (1993) 1.15
Ventriculus terminalis of the conus medullaris: MR imaging in four patients with congenital dilatation. AJNR Am J Neuroradiol (1991) 1.14
High-frequency jet ventilation for HIFU. Cardiovasc Intervent Radiol (2014) 1.10
Imaging of blunt chest trauma. Eur Radiol (2000) 1.09
Diagnostic performance of MRI for detection of intestinal fistulas in patients with complicated inflammatory bowel conditions. Eur Radiol (2007) 1.07
Papain-derived fragment IIc of tetanus toxin: its binding to isolated synaptic membranes and retrograde axonal transport. Brain Res (1981) 1.07
Studies on the mechanism of T cell-mediated lysis at the single effector cell level. I. Kinetic analysis of lethal hits and target cell lysis in multicellular conjugates. J Immunol (1979) 1.07
MRI of unusual lesions in the internal auditory canal. Neuroradiology (2001) 1.05
HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals. Proc Natl Acad Sci U S A (1990) 1.05
Chemical characterization of tetanus toxin and toxoid. Amino acid composition, number of SH and S-S groups and N-terminal amino acid. Eur J Biochem (1970) 1.04
Experimental modification of postnatal cerebellar granule cell migration in vitro. Brain Res (1986) 1.04
Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progression. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.03
Involvement of gangliosides in rabies virus infection. J Gen Virol (1986) 1.01
Interleukin-10-mediated T cell apoptosis during the T helper type 2 cytokine response in murine Schistosoma mansoni parasite infection. Eur Cytokine Netw (1997) 1.01
Hepatic nodules in Budd-Chiari syndrome: imaging features. Radiology (1999) 1.01
[Production and purification of tetanus toxin]. Ann Inst Pasteur (Paris) (1969) 1.00
Adeno-associated virus-mediated delivery of IL-4 prevents collagen-induced arthritis. Gene Ther (2000) 1.00
Direct analysis of individual killer T cells: susceptibility of target cells to lysis and secretion of hydrolytic enzymes by CTL. Adv Exp Med Biol (1982) 1.00
Ultrasound and Doppler micro-imaging in a model of rheumatoid arthritis in mice. Ann Rheum Dis (2008) 1.00
Hemomediastinum caused by rupture of a bronchial artery aneurysm: successful treatment by embolization with N-butyl-2-cyanoacrylate. J Vasc Interv Radiol (2001) 0.99
Tetanus toxin and botulinum A toxin inhibit release and uptake of various transmitters, as studied with particulate preparations from rat brain and spinal cord. Naunyn Schmiedebergs Arch Pharmacol (1981) 0.99
Use of Old World monkeys for acquired immunodeficiency syndrome research. J Med Primatol (1989) 0.98
Two distinct regions of cyclophilin B are involved in the recognition of a functional receptor and of glycosaminoglycans on T lymphocytes. J Biol Chem (1999) 0.98
Helical CT assessment in hilar cholangiocarcinoma: correlation with surgical and pathologic findings. AJR Am J Roentgenol (1999) 0.97
Randomized controlled trial of peripherally inserted central catheters vs. peripheral catheters for middle duration in-hospital intravenous therapy. J Thromb Haemost (2008) 0.96
IL-10 producing regulatory B cells in mice and humans: state of the art. Curr Mol Med (2012) 0.96
Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. Vaccine (1998) 0.95
Monoclonal antibodies against tetanus toxin and toxoid. Med Microbiol Immunol (1983) 0.95
Immunization against AIDS in humans. Nature (1987) 0.95
Characterization of surface binding sites for cyclophilin B on a human tumor T-cell line. J Biol Chem (1994) 0.95
Monoclonal antibodies to HIV in a non-infected, immunised volunteer. Lancet (1988) 0.94
Use of the B-IIb tetanus toxin derived fragment as a specific neuropharmacological transport agent. Brain Res (1980) 0.94
Naturally acquired antibodies to tetanus toxin in humans and animals from the galápagos islands. J Infect Dis (1983) 0.94
Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases. Cytokine Growth Factor Rev (2003) 0.94
[Immunological and biological study of subunits of tetanus toxin]. C R Acad Sci Hebd Seances Acad Sci D (1974) 0.93
Synoviocyte infection with adeno-associated virus (AAV) is neutralized by human synovial fluid from arthritis patients and depends on AAV serotype. Hum Gene Ther (2007) 0.93
Benign liver tumors. Magn Reson Imaging Clin N Am (1997) 0.93
Combined percutaneous antegrade and cystoscopic retrograde approach in the treatment of distal ureteric fistulae. Cardiovasc Intervent Radiol (1996) 0.92
A new cytokine (IK) down-regulating HLA class II: monoclonal antibodies, cloning and chromosome localization. Oncogene (1994) 0.92
On the structure of tetanus toxin. Naunyn Schmiedebergs Arch Pharmacol (1973) 0.92
Active immunization against murine TNFalpha peptides in mice: generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection. Vaccine (2004) 0.92
[Histoautoradiography study of immunoglobulin biosynthesis of mouse myeloma plasmacytes]. C R Acad Sci Hebd Seances Acad Sci D (1969) 0.91
Short- and long-term hemodynamic effects of transjugular intrahepatic portosystemic shunts: a Doppler/manometric correlative study. AJR Am J Roentgenol (1995) 0.91
[Purification and properties of streptococcal erythrogenic toxin]. Ann Inst Pasteur (Paris) (1968) 0.91
Involvement of alpha-interferon in HIV-1 induced immunosuppression. A potential target for AIDS prophylaxis and treatment. Biomed Pharmacother (1994) 0.91
Intraductal papillary mucinous tumors of the pancreas: helical CT with histopathologic correlation. Radiology (2000) 0.91
Acidemia and catecholamine output of the isolated canine adrenal gland. Am J Physiol (1967) 0.90
Involvement of the N-terminal part of cyclophilin B in the interaction with specific Jurkat T-cell binding sites. Biochem J (1996) 0.90
Life-threatening vascular complications after central venous catheter placement. Eur Radiol (2001) 0.89
Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 0.89
Tat toxoid as a component of a preventive vaccine in seronegative subjects. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 0.89